A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia
- PMID: 2570086
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia
Abstract
We carried out an 8-month double-blind clinical trial comparing haloperidol decanoate with fluphenazine decanoate in the maintenance treatment of 72 schizophrenic outpatients. A parallel-groups design was used with stratification by sex and injection interval (2, 3, or 4 weeks). The initial injection interval was based on pretrial maintenance treatment with fluphenazine esters. The dosage equivalency of haloperidol decanoate (1.5 cc or 75 mg) to fluphenazine decanoate (1 cc or 25 mg) used was 3:1. This remained approximately the same throughout a 2-month titration period with a flexible dose regimen, and a further 6-month period with a fixed dose regimen. No statistically significant differences in therapeutic effect were found between the drugs. Both drugs had a similar profile for drug-induced parkinsonism, but there was a trend for differences in masking tardive dyskinesia. Haloperidol and prolactin plasma concentrations were well correlated with dosage, with the exception of haloperidol concentrations in patients receiving injections at 2-week intervals.
Similar articles
-
Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.Acta Psychiatr Belg. 1982 Mar-Apr;82(2):216-23. Acta Psychiatr Belg. 1982. PMID: 7180558
-
Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.Int Clin Psychopharmacol. 1986 Jul;1 Suppl 1:41-51. Int Clin Psychopharmacol. 1986. PMID: 3549879 Clinical Trial.
-
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.Int Clin Psychopharmacol. 1986 Jul;1 Suppl 1:15-23. Int Clin Psychopharmacol. 1986. PMID: 3549878 Clinical Trial.
-
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.J Psychiatry Neurosci. 1994 Jul;19(4):254-64. J Psychiatry Neurosci. 1994. PMID: 7918346 Free PMC article. Review.
-
Clinical pharmacokinetics of the depot antipsychotics.Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003. Clin Pharmacokinet. 1985. PMID: 2864156 Review.
Cited by
-
Depot antipsychotic drugs. Place in therapy.Drugs. 1994 May;47(5):741-73. doi: 10.2165/00003495-199447050-00004. Drugs. 1994. PMID: 7520856 Review.
-
Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.Drugs. 2003;63(5):493-512. doi: 10.2165/00003495-200363050-00004. Drugs. 2003. PMID: 12600227 Review.
-
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD000459. doi: 10.1002/14651858.CD000459.pub3. Cochrane Database Syst Rev. 2018. PMID: 29409162 Free PMC article.
-
Fluphenazine decanoate (depot) and enanthate for schizophrenia.Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Cochrane Database Syst Rev. 2015. PMID: 25654768 Free PMC article.
-
Depot haloperidol decanoate for schizophrenia.Cochrane Database Syst Rev. 2000;1999(2):CD001361. doi: 10.1002/14651858.CD001361. Cochrane Database Syst Rev. 2000. PMID: 10796438 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical